Chinese Clinical Stage Biotech Firm InventisBio Closes $70M Series C Round

Login to View

Chinese clinical stage biotechnology company InventisBio Inc. announced on Monday the closing of a US$70 million series C round of financing led by Chinese private equity firm Advantech Capital and CMB International Capital, a wholly-owned subsidiary of China Merchants Bank (CMB).

China Money Network

Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Want to read this important story?

Access Over 11,000 stories and data posts over the past 8 years!

Register Now

Already have an account or paid subscription? Log in